Health Canada Approves Rybelsus for Heart Disease Prevention

New Cardiovascular Protection Indication

The regulatory approval marks Rybelsus as the first and only oral GLP-1 medication approved in Canada that provides both glycemic control and cardiovascular protection. The 7mg and 14mg tablet strengths are now indicated for this expanded use.

Health Canada issued a Notice of Compliance under the NOC/c policy for this new indication in January 2026, according to the official Health Product InfoWatch bulletin. The approval applies specifically to adults with Type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Regulatory Context

This indication expansion comes as Health Canada continues reviewing nine generic semaglutide applications following the patent expiration on January 4, 2026. The approval demonstrates ongoing innovation in the GLP-1 medication class, even as generic competition approaches.

Novo Nordisk's press release emphasized that Rybelsus maintains its position as the only oral GLP-1 formulation available in Canada with this dual indication. The company markets Ozempic and Wegovy injection formulations alongside the oral tablet.

Clinical Implications

The expanded indication means healthcare providers can now prescribe Rybelsus tablets specifically for cardiovascular risk reduction in qualifying patients. The oral formulation offers an alternative to injection-based semaglutide products for patients requiring both diabetes management and heart disease prevention.

Healthcare professionals can now consider Rybelsus for patients who may prefer oral administration over injections, provided they meet the specific cardiovascular risk criteria outlined in the new indication.

Market Impact

This approval occurs as the Canadian GLP-1 market prepares for generic semaglutide entry in mid-2026. Current pricing information and insurance coverage details for the expanded indication are available through our insurance coverage checker.

Provincial drug plans and private insurers will need to update their coverage policies to reflect the new cardiovascular indication. Patients can monitor developments through our generic semaglutide tracker as generic oral formulations may become available later in 2026.

Additional Resources

Patients seeking more information about GLP-1 medications and coverage options can consult our comprehensive FAQ section. Healthcare providers should review the complete prescribing information for specific patient eligibility criteria and dosing recommendations.